Theravance Biopharma (TBPH) Receivables - Net (2013 - 2019)

Theravance Biopharma (TBPH) has reported Receivables - Net for 7 consecutive years, with $87000.0 the latest figure, recorded in Q3 2019.

• In Q3 2019, Receivables - Net fell 97.12% year-over-year to $87000.0; the TTM figure through Sep 2019 stood at $87000.0 (down 97.12% YoY), while the FY2018 annual figure was $620000.0, down 72.48% from the prior year.
• Receivables - Net declined to $87000.0 in Q3 2019 per TBPH's latest filing, from $111000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $3.4 million in Q2 2018 and bottomed at $87000.0 in Q3 2019.
• Historically, Receivables - Net has averaged $1.3 million across 5 years, with a median of $1.2 million in 2017.
• Annual changes were most pronounced in 2015 — Receivables - Net soared 18733.33% — and 2019, when it plunged 97.12%.
• Theravance Biopharma's Receivables - Net stood at $1.9 million in 2015, then tumbled by 66.39% to $646000.0 in 2016, then soared by 248.76% to $2.3 million in 2017, then tumbled by 72.48% to $620000.0 in 2018, then sank by 85.97% to $87000.0 in 2019.
• Business Quant data shows TBPH's Receivables - Net at $87000.0 in Q3 2019, $111000.0 in Q2 2019, and $113000.0 in Q1 2019.